Question

In: Accounting

Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash...

Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 10.54 percent for such projects.

Year Product Line Expansion Production Capacity Expansion
0 -$3,146,400 -$9,369,900
1 741,600 2,699,400
2 895,900 2,699,400
3 895,900 2,699,400
4 895,900 3,978,600
5 895,900 3,978,600


a. What are the NPVs of the two projects? (Enter negative amounts using negative sign, e.g. -45.25. Do not round discount factors. Round other intermediate calculations and final answer to 0 decimal places, e.g. 1,525.)

NPV of product line expansion is $
NPV of production capacity expansion is $


b. Should both projects be accepted? or either? or neither? Explain your reasoning.

Cullumber should accept

only the production capacity expansionboth projectsneither projectonly the product line expansion

.

Solutions

Expert Solution

NPV of product line expansion

Year

Annual cash flows ($)

Present Value Factor (PVF) at 10.54%

Present Value of annual cash flows ($)

[Annual cash flow x PVF]

1

741,600

0.9046499

670,888

2

895,900

0.8183914

733,197

3

895,900

0.7403577

663,286

4

895,900

0.6697646

600,042

5

895,900

0.6059024

542,828

TOTAL

3,210,242

Net Present Value (NPV) = Present Value of annual cash inflows – Initial Investment

= $3,210,242 - $3,146,400

= $63,842

NPV of production capacity expansion

Year

Annual cash flows ($)

Present Value Factor (PVF) at 10.54%

Present Value of annual cash flows ($)

[Annual cash flow x PVF]

1

2,699,400

0.9046499

2,442,012

2

2,699,400

0.8183914

2,209,166

3

2,699,400

0.7403577

1,998,522

4

3,978,600

0.6697646

2,664,725

5

3,978,600

0.6059024

2,410,643

TOTAL

11,725,068

Net Present Value (NPV) = Present Value of annual cash inflows – Initial Investment

= $11,725,068 - $9,369,900

= $2,355,168

NPV of product line expansion is $63,842

NPV of production capacity expansion is $2,355,168

DECISION

Since,it is an independent projects, Cullumber can accept either both projects, because the NPV for the both projects are positive.

NOTE    

The Formula for calculating the Present Value Factor is [1/(1 + r)n], Where “r” is the Discount/Interest Rate and “n” is the number of years.


Related Solutions

Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash...
Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 14.98 percent for such projects. Year Product Line Expansion Production Capacity Expansion 0 -$2,426,500 -$6,756,300 1 501,800 2,381,500 2 853,000 2,381,500 3 853,000 2,381,500 4 853,000 3,975,200 5 853,000 3,975,200 a. What are the NPVs of the two projects? b. Should both projects be accepted?...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 14.08 percent for such projects. Year Product Line Expansion Production Capacity Expansion 0 -$2,233,600 -$9,704,800 1 478,900 2,611,700 2 980,500 2,611,700 3 980,500 2,611,700 4 980,500 3,361,400 5 980,500 3,361,400 a. What are the NPVs of the two projects? (Enter negative amounts using negative sign,...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 14.08 percent for such projects. Year Product Line Expansion Product capacity expansion 0 -$2,233,600 -$9,704,800 1 478,900 2,611,700 2 980,500 2,611,700 3 980,500 2,611,700 4 980,500 3,361,400 5 980,500 3,361,400 a. What are the NPVs of the two projects? (Enter negative amounts using negative sign,...
Sunland Industries is expanding its product line and its production capacity. The costs and expected cash...
Sunland Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 16.08 percent for such projects. Year Product Line Expansion Production Capacity Expansion 0 -$2,053,800 -$6,584,800 1 663,900 2,742,200 2 839,000 2,742,200 3 839,000 2,742,200 4 839,000 2,612,300 5 839,000 2,612,300 a. What are the NPVs of the two projects? (Enter negative amounts using negative sign,...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT